In September, Valneva signed a partnership with the U.K. government to supply up to 190 million doses of VLA2001, which consists of inactivated SARS-CoV-2 virus particles with high S-protein density combined with two adjuvants: alum and CpG 1018. It is the only inactivated vaccine candidate in clinical trials in Europe, according to Valneva. If the vaccine is developed successfully, Valneva will supply the U.K. government with 60 million doses in the second half of this year.
Phase I/II of the study began in December 2020 and includes 150 healthy adults. It will evaluate three dose levels of the vaccine for safety, tolerability, and immunogenicity in a two-dose schedule three weeks apart, Valneva said.
Copyright © 2021 scienceboard.net